Publications

Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, G Grass D, Jain RK et al..  2023.  Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.. Nat Rev Urol.

Zhu A, Garcia JAlberto, Faltas B, Grivas P, Barata P, Shoag JE.  2023.  Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer.. JAMA Netw Open. 6(4):e237444.

Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2022.  The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer.. Cancer Res.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

Liu W, Faltas BM.  2022.  Loss of function mutations in CDKN1A are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma.. Am J Cancer Res. 12(5):2419-2421.

Vlaar JM, Borgman A, Kalkhoven E, Westland D, Besselink N, Shale C, Faltas BM, Priestley P, Kuijk E, Cuppen E.  2022.  Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.. Sci Rep. 12(1):10081.

Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM et al..  2022.  Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. Br J Cancer.

Alnajar H, Ravichandran H, Rendeiro AFigueiredo, Ohara K, Zoughbi WAl, Manohar J, Greco N, Sigouros M, Fox J, Muth E et al..  2022.  Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. Cold Spring Harb Mol Case Stud. 8(3)

Yu H, Sfakianos JP, Wang L, Hu Y, Daza J, Galsky MD, Sandhu HS, Elemento O, Faltas BM, Farkas AM et al..  2022.  Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.. Mol Cancer Ther. 21(11):1729-1741.

Shohdy KS, Bareja R, Sigouros M, Wilkes DC, Dorsaint P, Manohar J, Bockelman D, Xiang JZ, Kim R, Ohara K et al..  2021.  Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors.. NPJ Genom Med. 6(1):66.

Khan U, Ho K, Hwang EKyeong, Peña C, Brouwer J, Hoffman K, Betel D, Sonnenberg GF, Faltas B, Saxena A et al..  2021.  Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment.. Am J Clin Oncol. 44(6):247-253.

Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.

Zoughbi WAl, Fox J, Beg S, Papp E, Hissong E, Ohara K, Keefer L, Sigouros M, Kane T, Bockelman D et al..  2021.  Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.. Oncologist.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Jiao W, Atwal G, Polak P, Karlic R, Cuppen E, Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N et al..  2020.  A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.. Nat Commun. 11(1):728.

Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.

Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L.  2020.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.. Nat Rev Urol.

Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupret M, Sfakianos JP, Shariat SF et al..  2020.  Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.. Eur Urol.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.  2020.  Pan-cancer analysis of whole genomes.. Nature. 578(7793):82-93.

Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3

Grivas P, Lalani A-KA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J et al..  2019.  Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.. Eur Urol Oncol.

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Vlachostergios PJ, Faltas BM.  2019.  The molecular limitations of biomarker research in bladder cancer.. World J Urol. 37(5):837-848.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.